DNMT3B and hepatocellular carcinoma: Their findings revealed that increased expression of DNMT3B in HCC patients was indicative of reduced overall survival rates, while HCC cases characterized by lower levels of DNMT3B expression exhibited a shorter duration of disease-free survival.